Connexion PharmaClik 
McKesson Canada
Améliorer les soins de santé pour tous ™
Nous touchons pratiquement tous les aspects de la santé
En tant que leader diversifié dans le domaine de la santé, nous offrons des solutions qui aident les patients à accéder à des thérapies qui changent leur vie. Qu’il s’agisse, entre autres, de livrer le tiers de tous les médicaments au Canada, d’accueillir les patients dans nos pharmacies ou d’établir des partenariats avec les parties prenantes du secteur de la santé, nous poursuivons notre objectif d'améliorer les soins de santé pour tous.
Améliorer les soins de santé pour tous ™
Nous touchons pratiquement tous les aspects de la santé
En tant que leader diversifié dans le domaine de la santé, nous offrons des solutions qui aident les patients à accéder à des thérapies qui changent leur vie. Qu’il s’agisse, entre autres, de livrer le tiers de tous les médicaments au Canada, d’accueillir les patients dans nos pharmacies ou d’établir des partenariats avec les parties prenantes du secteur de la santé, nous poursuivons notre objectif d'améliorer les soins de santé pour tous.
Distribution
Soins de santé spécialisés
Solutions pour les pharmacies de détail
Solutions technologiques d'automatisation
En vedette :
Médicaments pour les maladies rares au Canada : Considérations relatives pour un accès équitables
Favoriser un accès équitable aux traitements spécialisés et pour les maladies rares — en mettant à profit une expertise approfondie en soutien aux patients, en distribution et en services pharmaceutiques afin d’aider les Canadiens à obtenir les soins dont ils ont besoin, au moment où ils en ont besoin.
En vedette :
Médicaments pour les maladies rares au Canada : Considérations relatives pour un accès équitables
Favoriser un accès équitable aux traitements spécialisés et pour les maladies rares — en mettant à profit une expertise approfondie en soutien aux patients, en distribution et en services pharmaceutiques afin d’aider les Canadiens à obtenir les soins dont ils ont besoin, au moment où ils en ont besoin.
Histoires & perspectives
Le premier concours d’innovation de Roche Canada et McKesson Canada améliore l’expérience des patients
MISSISSAUGA, ON - January 11, 2024 - Hoffmann-La Roche Limited (Roche Canada) is proud to announce a dynamic collaboration with McKesson Canada (McKesson) which has resulted in solutions that will optimize the patient journey and potentially shorten overall time to therapy.
The two industry leaders brought collaborative teams together for an intensive six-week innovation challenge aimed at removing barriers, enhancing the patient experience, streamlining administrative processes, and expediting reimbursement within existing patient support programs. This collaboration demanded a creative approach to strategically design solutions within the constraints of available resources.
When a patient is diagnosed with a chronic condition or disease like Multiple Sclerosis (MS) or cancer, it can be challenging to navigate the complex healthcare systems. Patient Support Programs (PSPs) work to simplify the process and ease the patient’s experience.
“Roche created this innovation challenge to explore what could be possible in the patient support program space and to see what - with an open-minded partner like McKesson Canada - we could do differently, better, faster for patients,” said Roger Tam, Vice President, Legal, Compliance, and Innovation at Roche Canada. “Design thinking empowered Roche Canada and McKesson Canada employees to frame opportunities and create solutions that will deliver significant value to all stakeholders, especially patients.”
The innovation challenge culminated in a pitch competition, where teams presented their proposals to a seasoned panel of leaders from both Roche Canada and McKesson Canada. The pitches underwent rigorous evaluation, resulting in the prioritization of the highest-scoring proposal for implementation over the next six to 12 months. Ultimately, the panel found all solutions to be compelling enough for implementation; it was simply a matter of determining the optimal timeline for each.
The two winning innovations addressed the cumbersome administrative challenges experienced by both patients and healthcare providers during PSP enrolment. Through streamlined processes, these solutions not only minimize time and redundancy for all stakeholders but also significantly accelerate access to vital therapies.
“When you have a patient with a complex disease, you do everything you can to get them to critical treatment as fast as you can,” said Rebecca Yu, Vice President/General Manager, Biopharma Operations & Customer Experience, McKesson Canada. “The Roche McKesson Innovation Challenge shows what is possible when you change your approach, share a common goal and come together with committed partners. We are tremendously proud of our teams and inspired by the value they have created with new solutions that will positively impact care and experience for patients!”
McKesson Canada is a Patient Support Program partner to Roche Canada and works to simplify a patient’s health journey by helping them to navigate the various healthcare systems, including supporting the administration process to ensure timely access to treatment.
The success of this innovation challenge not only underscores Roche Canada and McKesson Canada’s ability to swiftly implement ideas but also marks a pivotal step towards fostering a proactive culture of idea sharing, collaboration and innovation. Roche Canada and McKesson remain committed to revolutionizing PSPs and setting a new standard for excellence in patient care and experience.
About Roche Canada
Patients and science are at the heart of everything we do. At Roche, our passion for science and our commitment to relentlessly pursuing the impossible for patients has made us one of the world’s leading pharmaceutical, in vitro diagnostics, and healthcare technology companies. And we’re adding our expertise in new areas, such as artificial intelligence, real world data collection and analysis and collaborating with many different sectors and industries.
We're an innovator across major disease areas, including oncology, infectious diseases, diabetes, ophthalmology, and diseases of the central nervous system.
Roche Canada was founded in 1931 and employs more than 1,800 people across the country through its Pharmaceuticals division in Mississauga, Ontario as well as its Diagnostics and Diabetes Care divisions in Laval, Quebec. For more information, please visit www.RocheCanada.com, or follow Roche Canada on LinkedIn, or on Twitter @RocheCanada.
About McKesson Canada
McKesson Canada is a diversified health-care services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with pharmaceutical companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson Canada is impacting virtually every aspect of health care at www.McKesson.ca
For information, contact:
Jennifer Mota
Roche Canada
Jennifer.mota@roche.com
Michelle Lee-Gracey
McKesson Canada
media@mckesson.ca
La Corporation McKesson procède à la clôture de la vente des entreprises canadiennes Rexall et Well.ca
December 31, 2024 (IRVING, Texas) – McKesson Corporation (NYSE: MCK) reported today that on December 30, 2024 it has closed the transaction announced in September 2024 to sell its Canada-based Rexall and Well.ca businesses to Birch Hill Equity Partners, a Canadian private equity firm. This transaction enables the Company to focus capital deployment and prioritize investments expanding its strategic oncology and biopharma growth platforms.
Additional details related to the divestiture can be found on the company’s Investor Relations website.
About McKesson Corporation
McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at McKesson.com and read Our Stories.
Cautionary Statements
Except for historical information, statements in this press release regarding McKesson’s capital deployment, investment and growth platforms constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that involve risks and uncertainties that could cause actual results to differ materially from those in those statements. It is not possible to identify all such risks and uncertainties. The reader should not place undue reliance on forward-looking statements, which speak only as of the date they are first made. Except to the extent required by law, the company undertakes no obligation to publicly update forward-looking statements. We encourage investors to read the important risk factors described in the company’s most recent Form 10-K filed with the Securities and Exchange Commission. These risk factors include, but are not limited to: we may be unsuccessful in achieving our strategic growth objectives; our use of third-party data is subject to limitations that could impede the growth of our data services business; we might be adversely impacted by changes in the economic environments in which we operate; and we might be adversely impacted by events outside of our control, such as widespread public health issues, natural disasters, political events and other catastrophic events.
Contacts
Investor Relations
Rachel Rodriguez
469-260-2556
Rachel.Rodriguez@McKesson.com
Media
Media@mckesson.ca
En vedette :
INVIVA : Le principal réseau de cliniques privées de perfusion au Canada agréées dans le traitement du cancer
Soins d’infusion accrédités, soutenus par plus de 300 infirmières — élargissant l’accès aux traitements contre le cancer et accompagnant les patients aux côtés des médecins et de la pharmacie McKesson SPS.
En vedette :
INVIVA : Le principal réseau de cliniques privées de perfusion au Canada agréées dans le traitement du cancer
Soins d’infusion accrédités, soutenus par plus de 300 infirmières — élargissant l’accès aux traitements contre le cancer et accompagnant les patients aux côtés des médecins et de la pharmacie McKesson SPS.
